Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers Biological signalling pathways are complex, overlapping and riddled with workarounds redundancy and failsafe mechanisms that frequently cause drug discovery campaigns (based on perfectly good hypotheses) to fail. This is one of the major reasons why many oncology projects in